News for Protara Therapeutics, Inc. (TARA)

**media[558065]**

Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC; Announcement of initial data from 12-month evaluable patients expecte

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.( TARA), a clinical-stage company developing transformative therapies for the treatment

On December 31, 2024, RA CAPITAL MANAGEMENT, L.P. (Trades, Portfolio) executed a noteworthy transaction by acquiring an additional 1,531,713 shares of Protara T

Recent Acquisition by Citadel Advisors LLC (Trades, Portfolio) On December 31, 2024, Citadel Advisors LLC (Trades, Portfolio) made a significant move by acquiri

Woodline Partners LP (Trades, Portfolio)'s Recent Acquisition On December 31, 2024, Woodline Partners LP (Trades, Portfolio) executed a significant transaction

On December 31, 2024, JANUS HENDERSON GROUP PLC (Trades, Portfolio) executed a notable transaction by acquiring 5,448,687 shares of Protara Therapeutics Inc (TA

Opaleye Management Inc. (Trades, Portfolio)'s Recent Acquisition On December 31, 2024, Opaleye Management Inc. (Trades, Portfolio) executed a strategic stock tr

**media[513604]**

On December 10, 2024, Velan Capital Investment Management LP (Trades, Portfolio) executed a significant transaction involving Protara Therapeutics Inc (TARA). T

Protara Therapeutics' TARA-002 showed promising Phase 2 results, significantly improving its valuation and offering a strong risk-reward setup despite...

NEW YORK, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. ( TARA), a clinical-stage company developing transformative therapies for the treatment

**media[489946]**

Protara Announces Closing of $100 Million Public Offering

NEW YORK, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the

Protara Therapeutics' TARA-002 shows promising early data in bladder cancer, with a 72% complete response rate at 6 months in a small phase 2 trial. Learn more on TARA stock here.

Stay updated on the latest advancements in bladder cancer treatment and the financial decisions of a leading company in the healthcare sector. Click to read.

Protara Therapeutics (TARA) announces pricing of $100 million public offering to fund clinical development, causing stock price to decline 6%.

China -based Universe Pharmaceuticals INC (UPC) is up over 184 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.